OncoMatch/Clinical Trials/NCT06123338
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Is NCT06123338 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for esophageal cancer.
Treatment: Pembrolizumab · Trastuzumab · Oxaliplatin · Capecitabine · 5-Fluorouracil · Docetaxel — The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Gastric Cancer
Biomarker criteria
Required: HER2 (ERBB2) overexpression (ihc 3+ or ihc 2+/fish>2.0)
Disease stage
Excluded: Stage IV
Presence of metastatic or recurrent disease [excluded]. Complete surgical resection of the primary tumor must be achievable
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 agent.
Cannot have received: anti-HER2 agent
Has received prior therapy with an anti-HER2 agent
Cannot have received: any therapy for esophagogastric cancer
Has received prior treatment for esophagogastric cancer
Lab requirements
Blood counts
Absolute neutrophil count (ANC): ≥1,500 /mcL; Platelets: ≥100,000 / mcL; Hemoglobin: ≥8 g/dL
Kidney function
Creatinine clearance: ≥ 50 mL/minute
Liver function
Serum total bilirubin: ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN. Except patients with Gilbert's disease (≤3x ULN); AST and ALT: ≤ 2.5 X ULN; Albumin: >3 mg/dL
Cardiac function
Left ventricular ejection fraction ≥50% within 1 month of screening by MUGA or echocardiogram. Patients with an ejection fraction 45-49% may be permissible in the absence of any cardiac symptoms, if cleared by a cardiologist, and per the investigator's discretion.
Demonstrate adequate organ function as defined in Table 1. Left ventricular ejection fraction <50% within 1 month of screening by MUGA or echocardiogram. Patients with an ejection fraction 45-49% may be permissible in the absence of any cardiac symptoms, if cleared by a cardiologist, and per the investigator's discretion.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital (Data Collection Only) · Boston, Massachusetts
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) · Commack, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify